Psoriasis Drugs Market Poised to Hit 20 Billion Dollars in 2025 says SNS Research in Latest Report

PITTSBURGH - EntSun -- SNS Research has released its latest market report, "Psoriasis Drugs Market: 2025 – 2035 – Opportunities, Challenges, Strategies & Forecasts," detailing the competitive, clinical, and commercial dynamics shaping the global psoriasis therapeutics landscape through the next decade.

Global spending on psoriasis drugs is projected to approach 20 Billion dollars by the end of 2025, driven by rising disease prevalence, broader diagnosis, and a sustained shift toward high-efficacy immunology agents. The report examines how manufacturers are recalibrating strategy as treatment expectations continue to rise and patient preference shifts toward convenient, non-injectable options.

The 214-page study includes coverage of 50-plus development pipeline candidates and profiles 66 companies operating across biologics, oral systemics, and advanced topical modalities. The analysis outlines key factors that will determine market positioning through 2035, with emphasis on late-stage development trends, therapeutic class momentum, and evolving competitive pressures.

More on EntSun News

• A Family Completes a Full Circumnavigation of the Globe in a Self-Contained Camper Van
• Former Google Search Team Member Launches AI-Powered SEO Consultancy in Las Vegas
• Q3 2025 Arizona Technology Industry Impact Report Highlights Shifting Job Demand, Semiconductor Momentum and Workforce Investment
• $6.4 Million Purchase of Construction Vehicles Plus New Dealership Agreement with Cycle & Carriage for Heavy Equipment Provider to Singapore Region
• Film Volt Group unveils FVG Studios as UK–Canada studio platform

Key Findings in the Report:

• Biologics remain the market's central growth driver. Interleukin inhibitors, particularly IL-17 and IL-23 agents such as Skyrizi and Tremfya, continue to anchor the category through strong efficacy and durable clearance rates.
• ​Oral immunomodulators represent the next major commercial opportunity. Pipeline concentration on TYK2 and other targeted pathways reflects increasing demand for biologic-level outcomes without injections.
• Biosimilar impact remains limited in the United States. Access constraints, contracting dynamics, and ongoing litigation have slowed adoption across TNF and IL-12/23 classes, extending the lifecycle of reference biologics.
• Innovation is expanding across systemics and topicals. Selective JAK inhibitors, next-generation PDE4 agents, and advanced topical combinations are gaining traction as developers seek to improve adherence and long-term outcomes.
• Industry consolidation continues to intensify. Acquisitions and platform partnerships underscore the strategic value of robust immunology portfolios and diversified modality positions.

The report concludes that long-term market leadership will depend on disciplined integration of clinical development progress with commercial execution, particularly in categories where convenience, durability of response, and differentiation remain decisive.

More on EntSun News

• CCHR Says Mounting Evidence of Persistent Sexual Dysfunction From Antidepressants Demands FDA Action
• Acmeware and Avo Partner to Bring Real-Time Data Integration to MEDITECH Customers
• New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year
• Mr. Irrelevant: For Everyone Who's Been Doubted
• Voices for Humanity Featuring Pastor Jeffrey Mack's Mission of Peace Wins Gold at Viddy Awards

The full "Psoriasis Drugs 2025 Market" report, is available at: https://www.snsresearch.com/psoriasis-drugs-market-report-2025.html

About SNS Research:
SNS Research is a U.S. based intelligence firm focused on the healthcare and pharmaceutical sectors. The company delivers independent market analysis, pipeline evaluations, and evidence-driven forecasts used by biopharmaceutical manufacturers, investors, government agencies, academic institutions, and regulatory organizations.

For enquiries, quotes, or additional information: info@snsintel.com